Meta-analysis of mesenchymal stem cell therapy for intrauterine adhesions: a comprehensive consideration of efficacy and safety

作者：Jiawei Gao, Xinyue Zhou, Nan Jiang, Yongjuan Zhang, Jianpeng Han, Tianyu Jia, Yanbiao Jiang, Xiaoling Ma, Haofei Shen · 发表于：Frontiers in Bioengineering and Biotechnology · 年份：2025 · DOI：10.3389/fbioe.2025.1619778 · 被引用次数：3 · 研究领域：Gynecological conditions and treatments、Intestinal and Peritoneal Adhesions、Endometriosis Research and Treatment

Background: Intrauterine adhesions (IUA), a common gynecological condition, often result from endometrial injury and fibrosis. Traditional therapies like hysteroscopic adhesiolysis and hormone therapy show limited efficacy in endometrial repair and high recurrence rates. Stem cell therapy, particularly using mesenchymal stem cells (MSCs), has emerged as a promising alternative. This meta-analysis evaluates the efficacy and safety of MSCs therapy for IUA. Methods: We systematically searched Embase, MEDLINE, and the Cochrane Library up to January 2025. Using random or fixed-effects models, we analyzed outcomes including pregnancy rates, endometrial thickness, menstrual improvement, and safety indicators. Subgroup analyses were performed based on stem cell sources and transplantation methods. Results: Twelve studies with 233 patients were included. Stem cell therapy significantly improved menstrual outcomes (RR = 34.54, 95%CI: [15.07-79.18]), pregnancy rates (RR = 21.86, 95%CI: [8.60-55.56]), live birth rates (RR = 18.00, 95%CI: [6.67-48.55]), and endometrial thickness (MD = 2.28mm, 95%CI: [1.60-2.96]). Subgroup analyses indicated that adipose-derived (MD = 3.34 mm) and menstrual blood-derived (MD = 3.62 mm) stem cells exhibited the highest efficacy. Safety data indicated mild abdominal pain in 5.15% and abnormal blood indices in 4.29% of patients, with no severe complications. Conclusion: Stem cell therapy may improve the reproductive prognosis of patients with IUA. Autologous ...